- Home
- Who We Are
About Us
Qu Biologics has attracted a team of life sciences professionals who are leaders in their respective fields.
- What We Do
What We Do
Qu Biologics’ SSIs restore innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease.
- Clinical Trials
Clinical Trials
Investigational treatment QBECO SSI is an immunotherapy aimed at restoring normal immune function to reverse the chronic inflammation underlying Crohn’s disease.
- Partner With Us
Partner With Us
To gain a better understanding of the root causes of disease and the potential benefits of novel immunotherapies, Qu Biologics has a number of university research collaborations.
- Qu In The News
- Careers
Careers
Join a team of innovators who have a passion to make a difference. In a short time, our ambitious team has achieved a number of major milestones and we have many big goals ahead.
- Contact Us
Investment
“SSIs are not designed for incremental improvements to the ‘standard of treatment’ – they are designed to re-invent, complement and replace the standard.”
– Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics
Supported by a committed group of investors
Qu Biologics is a private clinical-stage biotechnology company incorporated September 2007 in the province of British Columbia, Canada. Qu Biologics has raised CAD$40 million to date from high net worth and ultra high net worth individuals and angel investors and an additional $5M in federal Canadian government funding through the National Research Council Industrial Research Assistance Program (NRC-IRAP) and the Scientific Research and Experimental Development (SR&ED) Tax Incentive Program.
We believe that SSIs have the potential to revolutionize the treatment of cancer, Crohn’s disease, ulcerative colitis, multiple sclerosis, Alzheimer’s disease, rheumatoid arthritis and other chronic inflammatory diseases by restoring normal immune function and the body’s innate capacity to heal. We are passionate and innovative and committed to creating a team of excellence to achieve this goal and the potential of SSIs.
If you would like to learn more about the investment potential of Qu, we would like to hear from you. We are seeking additional funds and/or a pharmaceutical partnership to move our QBECO program in IBD through to the end of Phase 2 and to expand our clinical trial program to include additional indications in cancer (e.g., late-stage colon cancer, inoperable pancreatic cancer) and immune-related disease (e.g., COPD).
Rather than blocking or stimulating a specific receptor or pathway, SSI treatments are designed to restore the body’s normal immune response. We believe this new approach will revolutionize the way chronic disease is treated. If you are interested in investment opportunities and learning more about our novel treatment approach and the innovative team behind it, please enter your contact information here.
Qu Biologics’ Uniquely Positioned Oncology Platform
Please view our 13min presentation about the transformative potential of Qu’s SSIs in cancer.
